Trials / Completed
CompletedNCT02546310
Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase 1, Exploratory Study Investigating the Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- Nxera Pharma UK Limited · Industry
- Sex
- All
- Age
- 65 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
To determine if treatment with HTL0009936 will lead to changes in neural activity, measured using the fMRI BOLD signal and ASL, in brain areas that are associated with spatial and working memory, learning and executive functioning.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HTL0009936 | |
| DRUG | HTL0009936 matching placebo |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2015-09-10
- Last updated
- 2017-02-03
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02546310. Inclusion in this directory is not an endorsement.